266P Association of RAD51 and efficacy outcomes in patients with HER2-negative breast cancer (BC) and homologous recombination deficiency (HRD): Post-hoc analysis of the GeparOla trial.

Autor:	Villacampa, G.1 (AUTHOR), Filmann, N.2 (AUTHOR), Fasching, P.A.3 (AUTHOR), Balmaña, J.4 (AUTHOR), Karn, T.5 (AUTHOR), Marmé, F.6 (AUTHOR), Klare, P.7 (AUTHOR), Mueller, V.8 (AUTHOR), Schem, C.9 (AUTHOR), Fehm, T.N.10 (AUTHOR), Stickeler, E.11 (AUTHOR), Van Mackelenbergh, M.12 (AUTHOR), Felder, B.13 (AUTHOR), Nekljudova, V.14 (AUTHOR), Llop-Guevara, A.15 (AUTHOR), Denkert, C.16 (AUTHOR), Loibl, S.17 (AUTHOR), Serra, V.18 (AUTHOR)
Zdroj:	Annals of Oncology. 2024 Supplement 2, Vol. 35, pS326-S327. 2p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu